- Home
- KULR vs MIST Comparison
KULR vs MIST Comparison
Compare KULR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | MIST |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 163.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KULR | MIST |
|---|---|---|
| Price | $3.21 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $40.00 | $6.33 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,677,036.00 | N/A |
| Revenue This Year | $27.50 | N/A |
| Revenue Next Year | $164.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.92 | N/A |
| 52 Week Low | $2.15 | $0.63 |
| 52 Week High | $43.92 | $2.77 |
Technical Indicators
Market Signals| Indicator | KULR | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 76.40 |
| Support Level | $2.15 | $2.31 |
| Resistance Level | $2.76 | $2.49 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 94.35 | 89.81 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).